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Aim: The aim of this study is to evaluate the diagnostic accuracy and impact of the stereotactic vacuum-
assisted aspiration biopsy (VAB) as a surgical treatment for non-palpable breast lesions.
Methods: A retrospective analysis of the diagnostic and therapeutic management of lesions having
undergone VAB treatment was conducted. From February 2003 to September 2007, 525 stereotactic VABs
were performed on 504 women using an 11-gauge needle device. Of these, 201 lesions were treated
surgically. The concordance between VAB results and ﬁnal pathology report after surgical excision was
evaluated. Also examined was the impact of VAB on the quality of the surgical treatment.
Results: Stereotactic VABs performed with an 11-gauge device showed an underestimation rate of 23.8%
for atypical ductal or lobular hyperplasia (AH). For ductal carcinoma in situ (DCIS) the underestimation
rate was 31% and the underestimation rate for lobular carcinoma in situ (LCIS) was 14%. Only 38.2% of the
patients with non-palpable lesions (201/525) were treated surgically and only 4% (20/504) of the patients
underwent more than one surgical intervention. The VAB underestimation caused mistakes in the
planning of the surgical therapy in only 9 out of 201 interventions (4.4%).
Conclusions: This study conﬁrms the efﬁcacy of the VAB procedure in the diagnosis of non-palpable
breast lesions and demonstrates its usefulness in therapeutic surgical planning. VAB treatment allows for
the reduction of the number of surgical procedures required to diagnose and treat non-palpable breast
lesions.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Due to the increased use of mammography as a result of orga-
nized screening programs or technical improvements, the diag-
nosis of non-palpable breast lesions has dramatically increased. In
the past, the approach for non-palpable breast lesions was either
clinical follow-up or open surgical biopsy, even if surgical biopsy
was and is considered expensive, invasive and may cause intense
psychological stress to the patient. Moreover, 90% of the breast
abnormalities detected by mammography correspond to benign
lesions.1 Therefore in 90% of the cases, surgical biopsy would be
useless and could be considered an overtreatment. As a result, in
the 1990s several percutaneous breast biopsy devices for histo-
logical examination were developed. In the presence of non-Rovera).
ciates Ltd. Published by Elsevier Ltpalpable breast lesions, not detected by ultrasound (US), stereo-
tactic VAB is considered a reliable alternative to surgical biopsy.2–8
2. Patients and methods
In this study, 504 women with an average age of 57.2 years and
ranging from 32 years to 88 years old underwent vacuum-assisted
breast biopsies (VABs) and were enrolled from February 2003 to
September 2007, at the Department of Surgery of the University of
Insubria, in Varese, Italy. Out of the 525 stereotactic VABs per-
formed on the 504 women, 21 patients had double procedures.
Eleven patients were excluded because of incomplete data.
In all cases the biopsy was performed using the 11-gauge
Mammotome instrument associated with the Fischer prone-biopsy
table (Fischer Mammotest Plus/S Mammovision; Ethicon Endo-
surgery, Cincinnati, OH, USA).
Those patients with non-palpable breast lesions that were
discovered with mammography and not detected by US, wered. All rights reserved.
Table 2
Localization of the breast lesions.
Number
Upper outer quadrant 243
Upper inner quadrant 26
Lower outer quadrant 22
Lower inner quadrant 43
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a procedure. When the lesionwas visible by US, a stereotactic guide
was avoided and in order to study the lesion ﬁne-needle aspiration
cytology (FNAC) or US-guided core-needle biopsy (CB) was used.
Patients with whom the mammographic ﬁnding of the lesions
was surely malignant or benignwere excluded. In these cases FNAC
was performed to achieve the histological diagnosis. In the case of
dubious results, VAB was performed as an additional level of study.
Days before the VAB procedure took place, the surgeon thor-
oughly explained the technique to the patient and obtained
informed consent. Preoperative analyses (blood samples) were
performed a few days before the biopsy was done.
All VABs were performed in an ambulatory setting and the
patients were observed for a period of 4–5 h after the procedure
was completed. The average duration of the biopsy was 35 min,
ranging from 18 to 65 min.
The day following the procedure, the patient was invited to the
center for dressing removal and clinical evaluation. Furthermore,
a week after this visit the patient underwent an additional clinical
evaluation and unilateral mammogram.
No signiﬁcant intolerance of this procedure or pain was repor-
ted, apart from one patient who asked to interrupt the procedure.
3. Results
Of the 525 VABs performed, 305 (58.5%) were mammo-
graphically detected as foci of microcalciﬁcations. Table 1 shows in
detail the types of breast mammographic abnormalities detected in
this study.
Most of the lesions were localized in the upper outer quadrant
(UOQ) or at the junction of the upper quadrants. Tables 2 and 3
show the localizations of all the breast lesions per quadrant. In this
study, the localization of four lesions was unknown. No signiﬁcant
difference was observed among any sides of the breast lesions that
were biopsied: in 251 cases (47.8%) the right breast was involved
and in 274 cases (52.2%) the left breast had abnormalities.
3.1. Outcomes of stereotactic vacuum-assisted breast biopsy
Table 4 shows the ﬁnal pathologic outcomes of the breast
lesions obtained with VAB procedure. Of the 163 malignant lesions
excised by the VAB technique, there were 97 invasive carcinoma
(ductal or lobular) and 65 carcinoma in situ (58 ductal and 7
lobular). One lesion was diagnosed as an intraparenchymal lymph
node involved by breast MALT-type lymphoma. In 21 cases the
lesions contained foci of atypical ductal or lobular hyperplasia (AH).
3.2. Surgical intervention
The surgical treatment of VAB was offered to all the patients
with the diagnosis of epithelial malignancy or atypical hyperplasia
(AH). The patient diagnosed with the primary breast lymphomaTable 1
Mammographic abnormalities.
Number
Microcalciﬁcations 305
Parenchymal distortions 111
Nodules 94
Parenchymal thickening 8
Parenchymal distortions with microcalciﬁcations 1
Nodule with microcalciﬁcations 1
Nodule with parenchymal distortions 1
Unknown 4
Total 525received only chemotherapy treatment, and no surgery was
performed.
The surgical interventions were performed using needle-local-
ization or radio-guided occult lesion localization (ROLL) techniques.
In total 201 surgical interventions were performed to treat 166
malignant lesions, 21 AH and 14 benign lesions. Speciﬁcally, 130
quadrantectomies, 36 mastectomies, 31 surgical biopsies, 2 duc-
tectomies and 2 nodulectomies were performed. Additionally
among the mastectomies, 18 sentinel lymph node biopsies (SLNB)
were performed during the same intervention. In 3 of the 18 cases
(16.7%) axillary lymphadenectomies became necessary due to
positive intraoperative diagnosis of the SLN. In the subgroup of the
mastectomy patients, no additional surgery was required.
Simple quadrantectomies were performed in 21 cases and this
decision was made based on the pathology report of the VAB
showing carcinoma in situ in this group of patients. In total 109
quadrantectomies with SLN biopsies were performed and for 104
cases two procedures were performed during the same operation.
In this group, 8 cases had positive SLN, which necessitated axillary
lymphadenectomies. In one case the axillary lymphadenectomy
was performed during a second operation due to a ﬁnal pathology
report of the SLN, where metastasis was missed in the previous
intraoperative evaluation. Due to the underestimation of the lesion
from the VAB and a pathology diagnosis of carcinoma in situ, in two
cases it was necessary to amend the original therapeutic strategy by
undergoing a simple quadrantectomy. Furthermore, the ﬁnal
pathology report of both cases showed invasive carcinoma, neces-
sitating a SLNB, one of which was followed by an axillary lym-
phadenectomy due to intraoperative metastatic disease of the SLN.
The staging of the axillary lymph nodes was performed in
a separate surgical setting before the quadrantectomy for three
patients, due to the inability to perform an intraoperative exami-
nation of the SLN. It was determined where to perform a lympha-
denectomy during a second surgical setting to treat the lesion once
the outcome of the SLNBwas received. Nine quadrantectomieswith
SLNB needed a second surgical procedure as the surgical resection
margins were positive for carcinoma.3.3. Pathologic outcomes after VAB procedure
In total, 164 malignant lesions were diagnosed by surgical
excisions resulting in 114 invasive carcinomas, 41 DCIS, 7 LCIS and 2
ductal-lobular carcinomas in situ (Table 5). In addition, 22 benign
lesions and 15 AH were also detected.
Among the 341 benign lesions found on stereotactic VAB, 18
were referred to surgical intervention. In 5 cases, the clinical
diagnosis of the VABs proved to be underestimated. Of the 18Table 3
Localization of the breast lesions.
Number
Junction of outer quadrants 19
Junction of inner quadrants 19
Junction of upper quadrants 73
Junction of lower quadrants 18
Region under areola 58
Table 4
Final pathology after VAB procedure.
Number
Benign 341
Invasive mammary carcinoma 97
Ductal carcinoma in situ (DCIS) 58
Atypical ductal or lobular hyperplasia (AH) 21
Lobular carcinoma in situ (LCIS) 7
Lymphoma 1
Total 525
Table 6
Outcomes of excised AH lesions found on stereotactic VAB.
Number
AH (conﬁrmed) 11
Benign (therapeutic) 5
Ductal carcinoma in situ (DCIS) 2
Invasive mammary carcinoma 3
Total AH lesions on VAB 21
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invasive carcinoma, one as AH and one as DCIS at the surgical
excision. The AH did not change the therapeutic management,
hence the real underestimation rate of benign lesions was 22.2%
(4/18).
Findings from the 21 AH surgical excisions showed ﬁve patients
(23.8%) with an upgraded diagnosis: three patients were found to
have invasive carcinoma and two patients were found to have DCIS;
in 5 lesions no residual AH was found (Table 6).
Among the 58 DCIS lesions found on stereotactic VAB, 18 (31%)
previously sampled sites were upgraded to invasive carcinoma.
LCIS clinical underestimation occurred only in one case out of 7
(14%). Among invasive carcinoma lesions found on VAB, the surgical
excision conﬁrmed the diagnosis in 89 out of 97 cases (91.7%). In 8
cases, VAB had removed all the invasive components, therefore 7
cases only showed DCIS in the surgical excision, and for one case no
residual malignancy was found.4. Discussion
The awareness on the part of the female population regarding
breast cancer prevention brings millions of asymptomatic women
to undergo mammography screening each year. These screenings
generate a signiﬁcant increase in the diagnosis of non-palpable
breast lesions, some of which are not classiﬁed with certainty by
mammography and need further investigation to be precisely
identify.
When facing a suspicious breast lesion it is necessary to obtain
a conﬁrmation by using cyto-histological diagnostic tools that
permit the lowest possible invasiveness. In fact, the histological
diagnosis of breast lesions is mandatory in order to plan the most
appropriate therapeutic strategy for each patient. The aim is to
avoid both the excessive use of surgery and the failure to treat
a breast cancer diagnosis, which has been clinically misinterpreted.
With the number of women who undergo screenings and the
potential psychological distress of false-positive diagnosis and
general overall cost, mini-invasive procedures, like VAB, are
required to quickly assess breast abnormalities diagnosed with
mammography without having to perform surgical biopsies in
every case.
In the past, the gold standard reference test has been the open
surgical breast biopsy. The accuracy of open biopsy is high, esti-
mated as between 96% and 99%.9,10 However, today minimally
invasive biopsies have replaced open excisional biopsies for mostTable 5
Type of epithelial malignancy.
Number
Invasive mammary carcinoma 114
Ductal carcinoma in situ (DCIS) 41
Lobular carcinoma in situ (LCIS) 7
Lobular and ductal carcinoma in situ 2
Total 164patients with an unclear mammographic ﬁnding. Needle-localized
breast biopsies for non-palpable lesions is not 100% reliable. In
2–7% of cases, surgical excisions miss the lesions.9,11,12 ROLL has
been advocated as an alternative to the hooked-wire technique13
and is also considered easier to perform and less painful to the
patient. However, the two techniques are similar from the point of
view of accuracy: in a randomized trial of ROLL versus wire local-
ization, in 2% of the ROLL patients the procedure missed the
lesion.14 For this reason, percutaneous image-guided breast biopsy
is being increasingly used to diagnose breast lesions. Furthermore,
percutaneous biopsies are faster, less invasive, and less expensive
than surgical biopsies. Less tissue is removed, resulting in no
deformity in the breast and minimal to no scarring on subsequent
mammograms.6 Percutaneous breast biopsies allow one to achieve
histological diagnosis reserving any subsequent surgery to deﬁni-
tive treatment of the lesion (therapeutic instead of diagnostic
intervention). In comparison to open excisional biopsy, minimally
invasive techniques have the same or better precision, decrease the
psychological burdens of the patients, and reduce costs. In fact they
decrease the number of surgical procedures required in patients
with non-palpable breast lesions compared to diagnostic open
surgery.15,16 Reliable cyto-histological diagnosis allows the sched-
uling of a surgical treatment in a unique approach avoiding further
re-interventions.
An increasing number of needle and biopsy probes are available
that enable the retrieval of breast tissue either from stereotactic or
US or MRI-guidance. These tools include small-gauge needles and
cutting needles used in combination with guns and directional
vacuum-assisted devices. The operator must not only decide which
of these technologies to use, but also which size of needle or probe
is the most appropriate in each case. Cost, clinical context, and
likely diagnosis should inﬂuence the decision process.17 The choice
of stereotactic versus US-guidance depends on several factors
including equipment availability, lesion visibility and accessibility,
and preferences of operator and patient. The stereotactic guidance
may be used for all types of mammographic lesions that are not
detected by US, such as parenchymal distortions and micro-
calciﬁcations, but it requires dedicated equipment. The stereotactic
biopsy is essential in the study of non-palpable breast lesions
because microcalciﬁcations (detectable only with mammography)
are a characteristic feature of DCIS, which represents 20–40% of all
non-palpable breast cancers and 25% of breast cancers found in
screening procedures.18 Stomper et al.19 reported on 100 DCIS
cases: 72% of these cases presented solely as microcalciﬁcations by
mammography, whereas in this present study 92% of cases had
microcalciﬁcations.
Fine-needle aspiration (FNA) is a common and inexpensive
diagnostic method; however, limitations of this technique have
been demonstrated in several studies. The frequency of insufﬁcient
samples ranges from 8.5% to 46%.17 In the literature considerable
variability is highlighted in the sensitivity of FNAC (63–99%)20–22
and a high rate of false negatives that ranges from 0% to 10%.23–25
The diagnostic accuracy for DCIS and AH is low.26–28 The high
frequency of insufﬁcient samples of FNA biopsy and its low accu-
racy are substantial limitations, and have led to the increasing use
of larger tissue-acquisition devices for percutaneous biopsy of the
F. Rovera et al. / International Journal of Surgery 6 (2008) S104–S108 S107breast, such as the automated guns used to perform large-core
needle biopsy (CNB) and the directional vacuum-assisted devices
used for VAB.
Validation studies showed 87–96% concordance between
results of stereotactic 14-gauge CNB and surgery.29,30 Although the
14-gauge CNB is an excellent tool, it has some limitations. Obtain-
ing each specimen requires a separate insertion and removal of the
needle. If multiple specimens are obtained, the later samples are
often composed predominantly of blood rather than breast tissue.
Retrieval of calciﬁcations may also be difﬁcult. For a lesion to be
retrieved with the automated needle, it must be along the line of
ﬁre of the needle; this can be particularly difﬁcult for small lesions
or microcalciﬁcations. For some lesions with complex histology
(such as calciﬁcations containing AH and DCIS or DCIS and invasive
carcinoma) the CNB may provide incomplete characterization of
the histological ﬁndings.6,17
Directional VAB devices have several advantages compared with
automated needles. The vacuum can be used to suck the blood out
of the cavity during and at the end of the biopsy procedure. Because
of the use of vacuum, tissue can be acquired at a distance from the
probe, not just within the line of ﬁre. The probe needs only to be
inserted once; multiple specimens can be obtained from that single
insertion. Specimens are larger than those obtained with 14-gauge
CNB. Many authors have shown VAB to be superior to 14-gauge
CNB. With VAB, microcalciﬁcation retrieval is signiﬁcantly
improved. In fact the retrieval can be conﬁrmed histologically in
91–100% of the specimens obtained with VAB, while it is only seen
in 86–94% of those obtained with CNB.6 VAB also results in more
accurate characterization of lesions with complex histology,31,32
thanks to the ease of obtaining multiple specimens and a larger
volume of tissue. For subsequent operative planning, the histo-
logical differences between invasive carcinoma, DCIS and AH is of
major signiﬁcance. Despite the relatively large biopsy specimen,
VAB cannot completely avoid the problem of lesion upgrade in the
operative specimen. Nevertheless, several studies have docu-
mented the precision of VAB compared with CNB.
In this study 18 of 341 benign lesion diagnosed with VAB
underwent surgical intervention, and in 4 cases (22.2%) the lesions
were upgraded at the surgical specimens evaluation.With regard to
the underestimation of AH and DCIS, the results of the present
study are in agreement with the previously published works. In the
literature the underestimation rate of DCIS varies from 0% to 35.7%,
whereas this study found an underestimation rate of 31% (18/58).
In our study all 58 patients with a diagnosis of DCIS performed
with VAB underwent surgical intervention. Among this group
a second surgical procedure was required in two cases. In one case
the surgical resection margins were positive for disease therefore
a second look was necessary in order to achieve surgical clearance.
In the second case the underestimation of DCIS caused a mistake in
the surgical planning: the pathologic discovery of invasive carci-
noma in the surgical specimen necessitated a SLNB for a complete
staging of the axillary lymph nodes.
In the literature AH lesions represent 2–11% of the non-palpable
lesions evaluated with VAB.33 In this study AH lesions were 4% of
the total, and in 23.8% of cases the histological examination of the
surgical specimen upgraded the lesion to invasive cancer. Several
authors stress the need for surgical intervention in the case of
diagnosis of AH to VAB, given the frequent and persistent diag-
nostic error associated with this type of lesion.
In the present study all patients with AH lesions diagnosed with
VAB were referred to surgical intervention. Re-intervention for
surgical clearance was performed in those patients with under-
estimated AH lesions.
With the conventional approach adopted in the past, all 504
patients recruited in this study had undergone at least one surgicalprocedure for diagnosis: the excisional biopsy. For all patients that
were diagnosed with malignancy via an excisional biopsy, further
therapeutic action was necessitated. Due to underestimation of
lesions with VAB, in nine patients the previously planned surgical
therapy proved to be inadequate and needed to be modiﬁed to
achieve the therapeutic goal. For eight patients only one other
surgical procedure was required and only in one case did the
patient undergo three surgical interventions. In 11 cases a two-step
surgical approach was also required if the therapeutic plan proved
to be correct and the VAB diagnosis conﬁrmed. In total, only 4% of
the patients (20/504) underwent more than one surgical
procedure.
In this study about 60% of patients were not subjected to any
surgical intervention. In a recent study, Sigal-Zafrani et al.34
compared the surgical management of patients who underwent
VAB, CNB and surgical biopsies for breast microcalciﬁcations. In the
case of the surgical biopsy group, all of the patients were operated
on at least once, 22% were operated on twice and 0.5% of the
patients were operated on three times. In the VAB subgroup, 54% of
patients were not subjected to any intervention, 9% of patients were
operated on twice, and only 1% three times. Other studies have
shown that 67–84% of biopsies with suspicious lesions diagnosed
via VAB required only one surgery, versus 25–36% in cases diag-
noses by open biopsy surgery.4,5,35
5. Conclusions
This study conﬁrms that, for non-palpable breast lesions, VAB is
a viable alternative to surgical biopsy in terms of diagnostic
performances. The VAB procedure was well tolerated in the present
study and no serious complications were observed. For its safety,
tolerability and reliability, VAB has an important role in the diag-
nostic protocol of non-palpable breast lesions. The importance of
mini-invasive biopsy techniques, such as CNB and VAB, is essen-
tially strategic, because it helps to plan the most appropriate
surgical strategy by providing an accurate and reliable pathological
diagnosis. The VAB avoids surgery for most benign lesions and
reduces the number of surgical procedures in cases with malignant
lesions. This allows for treatment to be provided in a single step.
Thanks to histological preoperative diagnosis with VAB, it is
possible to offer a surgical treatment of higher quality, dramatically
reducing the number of re-interventions for oncological staging
and clearance.
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